SCHEMBL2794495

SCHEMBL2794495

CCC(=O)c1ccc(Cl)cc1S(=O)(=O)Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.45
▸ KDM4E B2RXH2 3/20 0.45
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ TRPV4 Q9HBA0 1/20 0.44
▸ HSP90AB1 P08238 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ HIF1A Q16665 1/20 0.42
▸ FLT1 P17948 3/20 0.41
▸ FLT4 P35916 3/20 0.41
▸ KDR P35968 3/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ KCNH2 Q12809 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ THRB P10828 1/20 0.40
▸ RECQL P46063 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ CHRNA7 P36544 2/20 0.39
▸ CYP2D6 P10635 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2795074 0.81 TRPV4 (0.47) ALDH1A1SMN1; SMN2MEN1KMT2ATRPV4
SCHEMBL28819794 0.79 SMN1; SMN2 (0.57) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL1144066 0.77 ALDH1A1 (0.69) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL29712843 0.77 ALDH1A1 (0.69) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL5452555 0.77 ABL1 (0.58) ALDH1A1KDM4ESMN1; SMN2TRPV4FLT1
SCHEMBL6331423 0.75 HSP90AB1 (0.67) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL11118433 0.75 ALDH1A1 (0.50) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL8022080 0.74 KCNH2 (0.49) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL16168328 0.74 ALDH1A1 (0.61) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL29444021 0.74 ALDH1A1 (0.49) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100168087-A1 BENZO[1,2,3]THIADIAZINE DERIVATES EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) 2010-07-01 — — US disclosed
EP-2061777-A1 BENZOÝ1,2,3¨THIADIAZINE DERIVATIVES Egis Gyogyszergyar Nyilvánosan Múködó Részvénytársaság (HU) 2009-05-27 — — EP disclosed
WO-2008020255-A1 BENZO[1,2,3]THIADIAZINE DERIVATIVES EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársagág (HU) 2008-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168087-A1 BENZO[1,2,3]THIADIAZINE DERIVATES SULT2A1, TPH1, CYP1A1 ALDH1A1 39/4885KDM4E 3186/4885SMN1; SMN2 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback